Q3 2018 EPS Estimates for Spark Therapeutics Inc (ONCE) Lowered by B. Riley
Spark Therapeutics Inc (NASDAQ:ONCE) – Analysts at B. Riley dropped their Q3 2018 earnings per share (EPS) estimates for Spark Therapeutics in a report issued on Wednesday, August 8th. B. Riley analyst M. Kumar now expects that the biotechnology company will post earnings per share of ($2.44) for the quarter, down from their previous forecast of ($1.68). B. Riley has a “Neutral” rating and a $74.00 price objective on the stock. B. Riley also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($2.27) EPS, FY2018 earnings at ($3.81) EPS, Q1 2019 earnings at ($1.01) EPS, Q2 2019 earnings at ($0.97) EPS, Q3 2019 earnings at ($0.78) EPS, Q4 2019 earnings at ($0.64) EPS, FY2019 earnings at ($3.67) EPS, FY2020 earnings at $1.75 EPS, FY2021 earnings at $3.54 EPS and FY2022 earnings at $3.58 EPS.
Other analysts have also issued reports about the company. William Blair reaffirmed a “buy” rating on shares of Spark Therapeutics in a report on Thursday, April 19th. Mizuho reaffirmed a “buy” rating and set a $91.00 target price on shares of Spark Therapeutics in a report on Tuesday, May 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $103.00 target price (up from $100.00) on shares of Spark Therapeutics in a report on Monday, April 30th. BMO Capital Markets set a $78.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, Stifel Nicolaus raised their target price on Spark Therapeutics from $64.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, May 9th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. Spark Therapeutics presently has a consensus rating of “Hold” and an average target price of $72.67.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.34). The company had revenue of $25.19 million for the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative return on equity of 17.33% and a negative net margin of 185.46%.
A number of hedge funds have recently modified their holdings of ONCE. Teachers Advisors LLC boosted its position in Spark Therapeutics by 11.1% during the fourth quarter. Teachers Advisors LLC now owns 53,624 shares of the biotechnology company’s stock worth $2,757,000 after purchasing an additional 5,356 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Spark Therapeutics in the fourth quarter valued at approximately $647,000. Xact Kapitalforvaltning AB purchased a new position in shares of Spark Therapeutics in the fourth quarter valued at approximately $208,000. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Spark Therapeutics in the first quarter valued at approximately $266,000. Finally, Alps Advisors Inc. lifted its position in shares of Spark Therapeutics by 22.6% in the first quarter. Alps Advisors Inc. now owns 49,632 shares of the biotechnology company’s stock valued at $3,305,000 after acquiring an additional 9,136 shares in the last quarter.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Featured Story: Earnings Per Share
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.